$RSLS
ReShape Lifesciences Inc. Stock $rsls

$rsls Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000142757019000120 Filed on November 08, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$4.050M	$333.0K	$386.0K
YoY Change	98.92%	-88.85%	-85.87%
Cost Of Revenue	$1.935M	$412.0K	$679.0K
YoY Change	1077.72%	-70.94%	-60.8%
Gross Profit	$2.115M	-$79.00K	-$293.0K
YoY Change	297.56%	-105.04%	-129.3%
Gross Profit Margin	52.22%	-23.72%	-75.91%
Selling, General & Admin	$4.496M	$2.489M	$4.332M
YoY Change	-76.66%	-57.35%	-40.25%
% of Gross Profit	212.58%
Research & Development	$247.0K	$1.174M	$1.788M
YoY Change	-95.68%	-50.42%	-46.66%
% of Gross Profit	11.68%
Depreciation & Amortization	$421.0K	$422.0K	$430.0K
YoY Change	-122.76%	-47.25%	-69.06%
% of Gross Profit	19.91%
Operating Expenses	$4.743M	$3.663M	$6.120M
YoY Change	-87.83%	-55.35%	-42.28%
Operating Profit	-$2.628M	-$3.742M	-$6.413M
YoY Change	-69.65%	-43.6%	-33.21%
Interest Expense	-$43.00K	$37.00K	-$295.0K
YoY Change	247.33%	-152.86%	417.54%
% of Operating Profit
Other Income/Expense, Net	-$22.21M	-$1.000K	-$59.00K
YoY Change	14191.14%	-97.5%	-37.23%
Pretax Income	-$25.36M	-$28.75M	-$16.51M
YoY Change	-34.48%	443.86%	-19.56%
Income Tax	-$307.0K	$0.00	-$586.0K
% Of Pretax Income
Net Earnings	-$25.06M	-$3.706M	-$6.767M
YoY Change	186.17%	-45.06%	-30.62%
Net Earnings / Revenue	-618.69%	-1112.91%	-1753.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$63.96M	-$106.4M	-$150.2M
COMMON SHARES
Basic Shares Outstanding	7.695M shares	35.58M shares	24.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.935M	$7.717M	$4.355M
YoY Change	-47.1%	1531.95%	134.14%
Cash & Equivalents	$14.06M	$19.40M	$13.51M
Short-Term Investments	$0.00	$0.00	$0.00
Other Short-Term Assets	$1.959M	$683.0K	$954.0K
YoY Change	-20.43%	-24.86%	11.32%
Inventory	$1.936M	$2.048M	$2.107M
Prepaid Expenses	$1.890M	$656.0K	$954.0K
Receivables	$285.0K	$238.0K	$447.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.24M	$22.35M	$17.02M
YoY Change	-36.35%	-36.7%	-45.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.081M	$1.117M	$1.038M
YoY Change	-37.84%	-28.94%	-31.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$586.0K	$563.0K
YoY Change	-100.0%	616.73%	603.75%
Total Long-Term Assets	$2.158M	$2.308M	$2.178M
YoY Change	24.09%	46.82%	43.86%
TOTAL ASSETS
Total Short-Term Assets	$18.24M	$22.35M	$17.02M
Total Long-Term Assets	$2.158M	$2.308M	$2.178M
Total Assets	$20.39M	$24.66M	$19.20M
YoY Change	-32.89%	-33.14%	-40.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$648.0K	$732.0K	$1.082M
YoY Change	-44.09%	-49.79%	-25.12%
Accrued Expenses	$4.112M	$5.876M	$343.0K
YoY Change	-14.85%	33.28%	-92.38%
Deferred Revenue	$424.0K	$283.0K	$320.0K
YoY Change	20.45%	-5.98%	5.96%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$5.000M
YoY Change	-100.0%	-100.0%	26.1%
Total Short-Term Liabilities	$3.977M	$3.905M	$10.09M
YoY Change	-76.92%	-46.37%	-2.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$4.579M	$0.00
YoY Change		-51.28%	-100.0%
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$567.0K	$687.0K	$722.0K
YoY Change	1081.25%	-92.73%	-88.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.977M	$3.905M	$10.09M
Total Long-Term Liabilities	$567.0K	$687.0K	$722.0K
Total Liabilities	$4.544M	$4.592M	$10.81M
YoY Change	-73.7%	-72.55%	-34.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$172.4M	-$167.5M	-$163.8M
YoY Change	15.92%	19.64%	22.88%
Common Stock	$188.3M	$187.6M	$172.2M
YoY Change	16.32%	17.13%	15.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.11M	$20.07M	$8.376M
YoY Change
Total Liabilities & Shareholders Equity	$20.39M	$24.66M	$19.20M
YoY Change	-32.89%	-33.14%	-40.87%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	-$25.06M	-$3.706M	-$6.767M
YoY Change	186.17%	-45.06%	-30.62%
Depreciation, Depletion And Amortization	$421.0K	$422.0K	$430.0K
YoY Change	-122.76%	-47.25%	-69.06%
Cash From Operating Activities	-$1.321M	-$4.280M	-$2.900M
YoY Change	-81.37%	-6.56%	-55.38%
INVESTING ACTIVITIES
Capital Expenditures	-$14.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$2.000M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.014M	$0.00	$0.00
YoY Change	-80.49%	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.398M	7.651M	5.427M
YoY Change	-106.22%	140.05%	-27.93%
NET CHANGE
Cash From Operating Activities	-1.321M	-4.280M	-2.900M
Cash From Investing Activities	-2.014M	0.000	0.000
Cash From Financing Activities	-1.398M	7.651M	5.427M
Net Change In Cash	-4.733M	3.371M	2.527M
YoY Change	-193.26%	-342.46%	147.75%
FREE CASH FLOW
Cash From Operating Activities	-$1.321M	-$4.280M	-$2.900M
Capital Expenditures	-$14.00K	$0.00	$0.00
Free Cash Flow	-$1.307M	-$4.280M	-$2.900M
YoY Change	-81.56%	-6.76%	-55.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001427570
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7694576	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OBALON THERAPEUTICS INC
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	467000	USD
CY2019Q3	obln	Accrued Customer Incentives Current AccruedCustomerIncentivesCurrent	178000	USD
CY2018Q4	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	624000	USD
CY2019Q3	obln	Accrued Legal And Professional Fees Current AccruedLegalAndProfessionalFeesCurrent	637000	USD
	obln	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-248000	USD
CY2019Q3	obln	Lease Liability Current LeaseLiabilityCurrent	557000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1979000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2207000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	161859000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	187574000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14000	USD
CY2019Q3	obln	Lease Liability Noncurrent LeaseLiabilityNoncurrent	687000	USD
CY2019Q3	obln	Lease Right Of Use Asset LeaseRightOfUseAsset	1191000	USD
	obln	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	301000	USD
	obln	Proceedsfrom Issuanceof Common Stockand Exerciseof Prefunded Warrants Netof Issuance Costs ProceedsfromIssuanceofCommonStockandExerciseofPrefundedWarrantsNetofIssuanceCosts	0	USD
	obln	Proceedsfrom Issuanceof Common Stockand Exerciseof Prefunded Warrants Netof Issuance Costs ProceedsfromIssuanceofCommonStockandExerciseofPrefundedWarrantsNetofIssuanceCosts	15014000	USD
	obln	Restructuring Charges Gross RestructuringChargesGross	1105000	USD
CY2019Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingAggregateIntrinsicValue	95000	USD
CY2019Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingNumber	49114	shares
CY2019Q3	obln	Sharebased Compensation Arrangementby Sharebased Payment Award Non Option Equity Instruments Vestedand Expectedto Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVestedandExpectedtoVestOutstandingWeightedAverageExercisePrice	11.87
CY2019Q3	obln	Stock Issued During Period Value Exerciseof Warrants StockIssuedDuringPeriodValueExerciseofWarrants	2000	USD
CY2019Q3	obln	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	9000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	160000	USD
	obln	Unpaid Stock Issuance Costs UnpaidStockIssuanceCosts	295000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1159000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	732000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	870000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	238000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	20000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1389000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1214000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1007000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1105000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	536000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	659000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	665000	USD
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	508000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	29000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	70000	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25968	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	42473	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5328	shares
CY2018Q4	us-gaap	Assets Assets	30386000	USD
CY2019Q3	us-gaap	Assets Assets	24657000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	28647000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	22349000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019Q3	us-gaap	Capitalized Contract Cost Amortization Period CapitalizedContractCostAmortizationPeriod	P1Y
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21187000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19380000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19400000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21108000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21552000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21187000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19380000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	444000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1807000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3925774	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2351333	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7724100	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2351333	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7724100	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2328512	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6748000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28621000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3706000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18763000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	352000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	283000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1418000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3919000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	412000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2323000	USD
CY2018Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	428000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
CY2019Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	361000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.47
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.05
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.07
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3805000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	724000	USD
CY2019Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2200000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-107000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-128000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	1569000	USD
	us-gaap	Gross Profit GrossProfit	3146000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	-79000	USD
	us-gaap	Gross Profit GrossProfit	171000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	135000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-724000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1448000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-632000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-209000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-69000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1823000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3097000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	537000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	117000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-805000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1604000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	634000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-363000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-70000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-164000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	37000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-448000	USD
	us-gaap	Interest Paid Net InterestPaidNet	473000	USD
	us-gaap	Interest Paid Net InterestPaidNet	700000	USD
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	12000	USD
CY2019Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	202000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	85000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1580000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	2048000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1090000	USD
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1885000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	288000	USD
CY2019Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	78000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1356000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	117000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	533000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	569000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	137000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	112000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	17279000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	4592000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30386000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24657000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17231000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3905000	USD
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	48000	USD
CY2019Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	687000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9930000	USD
CY2019Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10129000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13674000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14332000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2506000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24017000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17987000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-12126000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-9753000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-6745000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-28624000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8290000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6767000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-3706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18763000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	8204000	USD
	us-gaap	Operating Expenses OperatingExpenses	31451000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	3663000	USD
	us-gaap	Operating Expenses OperatingExpenses	18426000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6635000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28305000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3742000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18255000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1244000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	557000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	687000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	762000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	676000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2462000	USD
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	683000	USD
CY2018Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	121000	USD
CY2019Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	27000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1985000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1609000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-155000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	537000	USD
CY2019Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	144000	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	30000	USD
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	867000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9103000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2329000	USD
CY2019Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	656000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9973000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8659000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	24302000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2550000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	38000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	148000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3718000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3324000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1739000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1117000	USD
CY2019Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1500000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	20000000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2368000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8359000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1174000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5401000	USD
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	49	employee
CY2019Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.50
CY2019Q2	us-gaap	Restructuring Charges RestructuringCharges	1100000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1099000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2019Q2	us-gaap	Restructuring Reserve RestructuringReserve	568000	USD
CY2019Q3	us-gaap	Restructuring Reserve RestructuringReserve	424000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148754000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167517000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-167500000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2987000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3000000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7065000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7100000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	300000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	333000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2500000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2494000	USD
	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	three to six months
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	132000	USD
CY2019Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	118000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5836000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23092000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2489000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13025000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1007000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3610000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	659000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2300000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	50621	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	159765	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	336008	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445034	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.29
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.00
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	254911	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	52.52
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	409978	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	46.33
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.72
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	45.45
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.16
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y3M15D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M7D
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	2548000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	118	shares
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	148000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9822000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	581000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8074000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14718000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	35113000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	24424000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	16051000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	20153000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	13107000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	6518000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	8376000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	20065000	USD
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1945864	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1783793	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6061248	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3700538	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and trade accounts receivable, which are generally not collateralized. The Company limits its exposure to credit loss by placing its cash equivalents with high credit quality financial institutions and investing in high quality short-term debt instruments. The Company’s customers consist of physicians and institutions in the United States and one international distributor. The Company establishes customer credit policies related to its accounts receivable based on historical collection experiences within the various markets in which the Company operates, historical past-due amounts, and any specific information that the Company becomes aware of such as bankruptcy or liquidity issues of customers. </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font></div></div>

Files In Submission

Name	View Source	Status
0001427570-19-000120-index-headers.html	Edgar Link	pending
0001427570-19-000120-index.html	Edgar Link	pending
0001427570-19-000120.txt	Edgar Link	pending
0001427570-19-000120-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
obln-20190930.xml	Edgar Link	completed
obln-20190930.xsd	Edgar Link	pending
obln-20190930_cal.xml	Edgar Link	unprocessable
obln-20190930_def.xml	Edgar Link	unprocessable
obln-20190930_lab.xml	Edgar Link	unprocessable
obln-20190930_pre.xml	Edgar Link	unprocessable
obln-93019x10q.htm	Edgar Link	pending
obln311-93019.htm	Edgar Link	pending
obln312-93019.htm	Edgar Link	pending
obln321-93019.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RSLS
ReShape Lifesciences Inc. Stock $rsls

2019 Q4 Form 10-Q Financial Statement

#000142757019000120 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS ReShape Lifesciences Inc. Stock $rsls

2019 Q4 Form 10-Q Financial Statement

#000142757019000120 Filed on November 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RSLS
ReShape Lifesciences Inc. Stock $rsls